If these trials confirm the findings, benralizumab could become the first new therapy approved for eosinophilic exacerbations ...

Eosinophilic exacerbations make up ... "But it's appalling that this is the first new treatment for those suffering from asthma and COPD attacks in 50 years, indicating how desperately underfunded ...

For this purpose, it’s approved as an add-on treatment used with other treatments for eosinophilic asthma. You may be ... Disclaimer: Medical News Today has made every effort to make certain ...

Of four treatment response measures recorded at 6 months of mepolizumab treatment, an Asthma Control Questionnaire score was ...

NICE has also added extra restrictions to the drug’s use on top of its licensed use in severe eosinophilic asthma ... as it provides access to a new treatment option for these patients.” ...

EMA accepts for review GSK’s MAA for depemokimab for use in asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 09:00 Hrs [IST] GSK plc announced ...

A year ago, he became one of just 200 people selected to take part in the trial of a new asthma treatment, Benralizumab, that comes in the form of an injection. Mr Birch said "life has completely ...

A Potential Therapeutic Target for Steroid Resistant Asthma,” published in the December 2024 issue of Allergy and Immunology ...

Customs duty exemption in Budget for cancer drugs, rare diseases including SMA: Our Bureau, New Delhi Saturday, February 1, 2025, 15:20 Hrs [IST] The 36 life saving drugs and medi ...

For decades, the standard treatment for these potentially ... benralizumab could become the first new therapy approved for eosinophilic exacerbations of asthma and COPD in over 50 years.

London: GSK plc has announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorisation Application for the use of depemokimab in two indications.The ...